Gateway Investment Advisers’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$907K Buy
3,998
+466
+13% +$83K 0.01% 456
2026
Q1
$609K Buy
3,532
+194
+6% +$36K 0.01% 437
2025
Q4
$666K Buy
+3,338
New +$605K 0.01% 415
2024
Q3
Sell
-978
Closed -$202K 515
2024
Q2
$202K Sell
978
-467
-32% -$106K ﹤0.01% 503
2024
Q1
$392K Sell
1,445
-35
-2% -$8.36K ﹤0.01% 417
2023
Q4
$350K Buy
1,480
+224
+18% +$44.1K ﹤0.01% 419
2023
Q3
$246K Sell
1,256
-178
-12% -$36.5K ﹤0.01% 456
2023
Q2
$301K Sell
1,434
-31
-2% -$6.17K ﹤0.01% 433
2023
Q1
$296K Sell
1,465
-27
-2% -$6.12K ﹤0.01% 445
2022
Q4
$325K Buy
1,492
+229
+18% +$50K ﹤0.01% 452
2022
Q3
$249K Sell
1,263
-658
-34% -$142K ﹤0.01% 474
2022
Q2
$411K Buy
1,921
+322
+20% +$78.7K ﹤0.01% 449
2022
Q1
$454K Sell
1,599
-95
-6% -$29.3K ﹤0.01% 444
2021
Q4
$638K Buy
1,694
+144
+9% +$55.9K 0.01% 386
2021
Q3
$640K Hold
1,550
0.01% 390
2021
Q2
$573K Sell
1,550
-295
-16% -$98.5K 0.01% 412
2021
Q1
$535K Sell
1,845
-298
-14% -$82.8K 0.01% 408
2020
Q4
$535K Buy
2,143
+15
+0.7% +$3.57K 0.01% 402
2020
Q3
$482K Sell
2,128
-85
-4% -$17.6K 0.01% 396
2020
Q2
$386K Sell
2,213
-192
-8% -$30.6K ﹤0.01% 439
2020
Q1
$304K Buy
2,405
+194
+9% +$29.1K ﹤0.01% 453
2019
Q4
$338K Sell
2,211
-259
-10% -$35.9K ﹤0.01% 473
2019
Q3
$327K Hold
2,470
﹤0.01% 498
2019
Q2
$350K Sell
2,470
-85
-3% -$11.5K ﹤0.01% 612
2019
Q1
$371K Sell
2,555
-118
-4% -$15.5K ﹤0.01% 609
2018
Q4
$303K Buy
2,673
+68
+3% +$8.51K ﹤0.01% 628
2018
Q3
$350K Hold
2,605
﹤0.01% 617
2018
Q2
$292K Buy
+2,605
New +$282K ﹤0.01% 635

Other funds holding CRL

Gateway Investment Advisers's CRL Position: Q2 2026 in Review

Gateway Investment Advisers increased its Charles River Laboratories (CRL) stake by 13% in Q2 2026, buying an estimated $83K and bringing the position to 3,998 shares worth $907K. The position accounts for 0.01% of the portfolio, ranked #456.

Gateway Investment Advisers first reported a position in CRL in Q2 2018 and has held it in 28 quarters since. 93 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Gateway Investment Advisers held 3,998 shares of Charles River Laboratories worth $907K as of Q2 2026.
  • Gateway Investment Advisers bought 466 Charles River Laboratories shares in Q2 2026, an estimated $83K.
  • Charles River Laboratories made up 0.01% of Gateway Investment Advisers's portfolio in Q2 2026, its #456 holding.
  • Gateway Investment Advisers first reported a position in Charles River Laboratories in Q2 2018 and has held it in 28 quarters since.
  • 93 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Gateway Investment Advisers's 13F filing for Q2 2026, filed 20 Jul 2026.